RC
INDV icon

Riposte Capital’s Indivior Pharmaceuticals INDV Stock Holding History

Riposte Capital’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-200,000
Closed -$6.1M – 32
2026
Q1 		$6.1M Buy
+200,000
New +$6.61M 1.55% 21

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Riposte Capital's INDV Position: Q2 2026 in Review

Riposte Capital sold out of Indivior Pharmaceuticals (INDV) in Q2 2026, closing a stake of 200,000 shares — an estimated $6.1M sold.

Riposte Capital first reported a position in INDV in Q1 2026 and held it in 1 quarter. The position peaked at $6.1M in Q1 2026. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Riposte Capital reported no remaining Indivior Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Riposte Capital sold 200,000 Indivior Pharmaceuticals shares in Q2 2026, an estimated $6.1M.
  • Riposte Capital first reported a position in Indivior Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Riposte Capital's Indivior Pharmaceuticals position peaked at $6.1M in Q1 2026.
  • 338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Riposte Capital's 13F filing for Q2 2026, filed 14 Aug 2026.